

Advanced non-small cell lung cancer – treatment with Pembrolizumab

 Antonio Silvinato¹
 Idevaldo Floriano¹
 Wanderley Marques Bernardo²

1. Associação Médica Brasileira, São Paulo, SP, Brasil

2. Coordenador do Programa Diretrizes da Associação Médica Brasileira, São Paulo, SP, Brasil

Contact: wmbernardo@usp.br

<http://dx.doi.org/10.1590/1806-9282.66.3.256>

Question: What is the impact of pembrolizumab, associated or not to chemotherapy, on the outcomes of overall mortality (death from any cause) and adverse events in the treatment of patients with advanced NSCLC when compared to chemotherapy alone?¹

Answer: The treatment with Pembrolizumab, associated or not with chemotherapy, in adult patients with squamous or non-squamous NSCLC, locally advanced or metastatic, without previous systemic therapy, without mutations in the EGFR gene and

gene rearrangement of the ALK, with a score of 0 or 1 in the ECOG performance scale, with at least one measurable lesion evaluated by Recist version 1.1, and PD-L1 expression [Tumor Proportion Score (TPS)] $\geq 1\%$ (positive PDL-1). High quality of evidence.

REFERENCE

1. Silvinato A, Floriano I, Bernardo WB – Advanced non-small cell lung cancer – treatment with Pembrolizumab - REV ASSOC MED BRAS 2019; 65(12):1423-1432

